CN1319987C - γ－分泌酶抑制剂 - Google Patents

γ－分泌酶抑制剂 Download PDF

Info

Publication number
CN1319987C
CN1319987C CNB038118963A CN03811896A CN1319987C CN 1319987 C CN1319987 C CN 1319987C CN B038118963 A CNB038118963 A CN B038118963A CN 03811896 A CN03811896 A CN 03811896A CN 1319987 C CN1319987 C CN 1319987C
Authority
CN
China
Prior art keywords
leu
val
glu
thr
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038118963A
Other languages
English (en)
Chinese (zh)
Other versions
CN1656115A (zh
Inventor
森启
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN1656115A publication Critical patent/CN1656115A/zh
Application granted granted Critical
Publication of CN1319987C publication Critical patent/CN1319987C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CNB038118963A 2002-04-24 2003-04-18 γ－分泌酶抑制剂 Expired - Fee Related CN1319987C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP121983/2002 2002-04-24
JP2002121983 2002-04-24

Publications (2)

Publication Number Publication Date
CN1656115A CN1656115A (zh) 2005-08-17
CN1319987C true CN1319987C (zh) 2007-06-06

Family

ID=29267426

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038118963A Expired - Fee Related CN1319987C (zh) 2002-04-24 2003-04-18 γ－分泌酶抑制剂

Country Status (11)

Country Link
US (1) US7585938B2 (pt)
EP (1) EP1498421B1 (pt)
JP (1) JP4404643B2 (pt)
KR (1) KR101051249B1 (pt)
CN (1) CN1319987C (pt)
AT (1) ATE448242T1 (pt)
AU (1) AU2003235283A1 (pt)
BR (1) BR0304562A (pt)
DE (1) DE60329995D1 (pt)
NO (1) NO329184B1 (pt)
WO (1) WO2003091278A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
WO2008055924A1 (en) * 2006-11-07 2008-05-15 Vib Vzw Diagnosis and treatment of t-cell acute lymphoblastic leukemia
JP5379692B2 (ja) 2006-11-09 2013-12-25 プロビオドルグ エージー 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体
JP5523107B2 (ja) 2006-11-30 2014-06-18 プロビオドルグ エージー グルタミニルシクラーゼの新規阻害剤
ZA200905537B (en) 2007-03-01 2010-10-27 Probiodrug Ag New use of glutaminyl cyclase inhibitors
ES2533484T3 (es) 2007-04-18 2015-04-10 Probiodrug Ag Derivados de tiourea como inhibidores de la glutaminil ciclasa
US8501813B2 (en) 2007-08-09 2013-08-06 Kabushiki Kaisha Yakult Honsha γ-secretase inhibitor
EA022007B1 (ru) 2009-09-11 2015-10-30 Пробиодруг Аг Гетероциклические производные в качестве ингибиторов глутаминилциклазы
WO2012144972A2 (en) * 2010-01-19 2012-10-26 The General Hospital Corporation Methods to inhibit neurodegeneration
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
KR101790806B1 (ko) 2010-03-10 2017-11-20 프로비오드룩 아게 글루타미닐 사이클라제(ｑｃ, ｅｃ 2.3.2.5)의 헤테로사이클릭 억제제
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
CN102344485A (zh) * 2010-08-05 2012-02-08 中国人民解放军军事医学科学院毒物药物研究所 用于治疗阿尔茨海默病的肽类β分泌酶抑制剂及其用途
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053255A1 (en) * 2000-01-24 2001-07-26 Merck Sharp & Dohme Limited Gamma-secretase inhibitors
US20020013276A1 (en) * 2000-03-02 2002-01-31 Nadin Alan John Investigational compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0236734A3 (de) * 1986-02-07 1988-05-11 Ciba-Geigy Ag Durch schwefelhaltigen Gruppen substituierte 5-Amino-4-hydroxyvalerylderivate
ATE339496T1 (de) * 2000-05-11 2006-10-15 Scios Inc Modulation von gamma-secretase aktivität
US20030022251A1 (en) * 2001-07-04 2003-01-30 Boehringer Ingelheim Pharma Kg Gamma-secretase in vitro screening assay

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053255A1 (en) * 2000-01-24 2001-07-26 Merck Sharp & Dohme Limited Gamma-secretase inhibitors
US20020013276A1 (en) * 2000-03-02 2002-01-31 Nadin Alan John Investigational compounds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A substrate-based difluoro ketone selectively inhibitsAlzheimer`s gamma-secretase activity Wolfe M.S. et al,J.Med.Chem.,Vol.41 No.1 1998 *
Distinct intramembrane cleavage of the beta-amyloidprecursor protein family resembling gamma-secretase-likecleavage of Notch Gu Y. et al,J. Biol. Chem.,Vol.276 No.38 2001 *
L-685,458, an aspartyl protease transition state mimic,is apotent inhibitor of amyloid beta-protein precursorgamma-sccretase activity Shearman M.S. et al,Biochemistry,Vol.39 No.30 2000 *

Also Published As

Publication number Publication date
KR101051249B1 (ko) 2011-07-21
NO20035535L (no) 2004-02-19
ATE448242T1 (de) 2009-11-15
EP1498421B1 (en) 2009-11-11
NO20035535D0 (no) 2003-12-11
NO329184B1 (no) 2010-09-06
WO2003091278A1 (fr) 2003-11-06
BR0304562A (pt) 2004-07-20
DE60329995D1 (de) 2009-12-24
AU2003235283A1 (en) 2003-11-10
US7585938B2 (en) 2009-09-08
JP4404643B2 (ja) 2010-01-27
KR20040106370A (ko) 2004-12-17
CN1656115A (zh) 2005-08-17
EP1498421A4 (en) 2006-05-17
US20060205666A1 (en) 2006-09-14
EP1498421A1 (en) 2005-01-19
JPWO2003091278A1 (ja) 2005-09-02

Similar Documents

Publication Publication Date Title
CN1319987C (zh) γ－分泌酶抑制剂
CN1058013C (zh) 新的巯基乙酰基酰胺衍生物的制备方法
CN1046525C (zh) 含有稠合双环的化合物及其制备方法
CN1106003A (zh) 微粒体甘油三酯转移蛋白的抑制剂和方法
CN1946718A (zh) 用作丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的具有环p4′s的新型酮酰胺
CN1950393A (zh) 丙型肝炎病毒ns3蛋白酶的抑制剂
CN1016778B (zh) 螺-取代的戊二酸单酰胺
CN1214011C (zh) 作为整联蛋白拮抗剂的间－氮杂环氨基苯甲酸化合物及其衍生物
CN1067883A (zh) 纤维蛋白原受体拮抗剂
CN1678578A (zh) 具有抗糖尿病活性的吲哚化合物
CN1072180A (zh) 取代的联苯吡啶酮
CN1067244A (zh) 吡咯烷酮
CN1134148A (zh) 抗血栓形成的脒基苯丙氨酸和脒基吡啶丙氨酸的衍生物
CN1875005A (zh) 阻断γ－分泌酶活性的丙二酰胺衍生物
CN1443173A (zh) 作为TAFIa抑制剂的取代的咪唑
CN1032751C (zh) 噻唑烷化合物，其制备及其治疗用途
CN1400968A (zh) 制备α－磺酰基异羟肟酸衍生物的方法
CN1170842C (zh) 新的脒基苄基胺衍生物及其作为凝血酶抑制剂的用途
CN1024659C (zh) 苯酚衍生物的制造和应用
CN1028173C (zh) 制备噁唑衍生物的方法
CN1035509A (zh) 头孢菌素类衍生物及其制备方法
CN1033991A (zh) 取代羟胺类
CN1086825A (zh) 三环和四环化合物
CN1835969A (zh) 冯希普尔－林道肿瘤抑制蛋白对低氧诱导因子－1的条件调节机制
CN1241940C (zh) 新型胶原蛋白样蛋白clac、其前体和它们的编码基因

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070606

Termination date: 20140418